BioSpace News Archive

Elicio Therapeutics announced that interim data from the Phase 1 study of its lead asset, ELI-002, will be presented in a poster discussion presentation at the upcoming 2023 American Society of Clinical Oncology Annual Meeting, a hybrid event taking place online and at McCormick Place in Chicago from June 2-6, 2023.

Mineralys Therapeutics, Inc. announced it will report its financial results from the first quarter ended March 31, 2023, after the financial markets close on Monday, May 15, 2023.

IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, is pleased to announce the appointment of Jeremy Graff, Ph.D., to its Board of Directors.

Akari Therapeutics, Plc today announced financial results and highlights for the full year ended December 31, 2022, as well as recent company updates.

Immutep Limited announces it has received regulatory approval from the Paul-Ehrlich-Institut, German Federal Institute for Vaccines and Biomedicines, to initiate INSIGHT-005, an investigator-initiated, open-label Phase I trial evaluating the safety and efficacy of eftilagimod alpha in combination with BAVENCIO® in up to 30 patients with metastatic urothelial carcinoma.

OrthoPediatrics Corp. a company focused exclusively on advancing the field of pediatric orthopedics, announced its continued support of the 2023 Pediatric Orthopaedic Society of North America annual meeting this week in Nashville, Tennessee.

Erasca, Inc. (Nasdaq: ERAS) today announced the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to ERAS-801 for the treatment of adult patients with glioblastoma (GBM) with epidermal growth factor receptor (EGFR) gene alterations.

BIOXYTRAN, INC. announced that Bioxtran CCO Michael Sheikh will be discussing the medical and scientific communities’ reaction to the latest peer reviewed journal article on the Emerging Growth Conference on May 3, 2023 at 12:35 pm EST.

Esperovax, Inc., a leading oral RNA vaccine and therapeutic technology company specializing in oral mRNA-based medicines,

OmniAb, Inc. (Nasdaq: OABI) will report financial results for the three months ended March 31, 2023 before the open of the U.S. financial markets on Thursday, May 11, 2023 and will hold a conference call that same day beginning at 8:30 a.m. Eastern time.